Literature DB >> 4207022

Gold kinetics following aurothiomalate therapy: use of a whole-body radiation counter.

R C Gerber, H E Paulus, R I Jennrich, M Lederer, R Bluestone, W H Blahd, C M Pearson.   

Abstract

Mesh:

Substances:

Year:  1974        PMID: 4207022

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


× No keyword cloud information.
  11 in total

Review 1.  Clinical pharmacokinetics of oral and injectable gold compounds.

Authors:  K L Blocka; H E Paulus; D E Furst
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

Review 2.  Monitoring gold plasma levels in rheumatoid arthritis.

Authors:  A Lorber
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

3.  Aurothioglucose overdosage in five patients with rheumatoid arthritis.

Authors:  I Rubinstein; P Langevitz; M Pras
Journal:  Clin Rheumatol       Date:  1987-12       Impact factor: 2.980

4.  Gold binding to blood cells and serum proteins during chrysotherapy.

Authors:  R J van de Stadt; B Abbo-Tilstra
Journal:  Ann Rheum Dis       Date:  1980-02       Impact factor: 19.103

5.  Therapeutic trials in muscular dystrophy. 1. Gold in murine dystrophy.

Authors:  A Enomoto; W G Bradley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-05       Impact factor: 10.154

Review 6.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

7.  Comparative pharmacokinetics of triethylphosphine gold (auranofin) and gold sodium thiomalate (GST).

Authors:  D E Furst; S H Dromgoole
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

Review 8.  Remission-inducing drugs in rheumatoid arthritis.

Authors:  T P Anastassiades
Journal:  Can Med Assoc J       Date:  1980-02-23       Impact factor: 8.262

Review 9.  Disease-modifying antirheumatic drugs. Potential effects in older patients.

Authors:  G Gardner; D E Furst
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 10.  Clinical pharmacokinetics of slow-acting antirheumatic drugs.

Authors:  S E Tett
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.